Avecia Biotechnology has entered an agreement with Pfizer for the commercial supply of a key component of Pfizer’s Macugen (pegaptanib sodium injection). Pfizer markets the drug in the E.U. for the treatment of wet Age-Related Macular Degeneration. The agreement includes technology transfer, process validation and commercial supply of a key component of Macugen. “The agreement with Pfizer to manufacture a key component of this commercial oligonucleotide-based therapeutic is testament to our e...